<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961753</url>
  </required_header>
  <id_info>
    <org_study_id>Ibuprofendosingstudy</org_study_id>
    <nct_id>NCT00961753</nct_id>
  </id_info>
  <brief_title>Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates</brief_title>
  <acronym>OIDS</acronym>
  <official_title>Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSF Healthcare System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OSF Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if increasing the ibuprofen dose will increase the
      likelihood of closing the patent ductus arteriosus in premature babies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Failure to close the PDA in premature neonates in a timely fashion can lead to pulmonary
      over-circulation and systemic under-circulation. The PDA often fails to close using currently
      approved Ibuprofen dosing regimens, and surgical closure becomes necessary. Ibuprofen
      clearance in premature neonates is significantly correlated with postnatal age, increasing
      rapidly over time. Hirt et al. published and optimized dosing scheme for preterm neonates
      based on pharmacokinetic and pharmacodynamic data. We aim to use this dosing regimen in the
      clinical setting to determine if increased rates of pharmacologic PDA closure can be
      achieved.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    FDA drug recall on July 30, 2010
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PDA Closure</measure>
    <time_frame>1-42 days of age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>1-30 days of age</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Optimized Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimized ibuprofen</intervention_name>
    <description>day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals</description>
    <arm_group_label>Optimized Ibuprofen</arm_group_label>
    <other_name>neoprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Ibuprofen</intervention_name>
    <description>day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals</description>
    <arm_group_label>Standard Ibuprofen</arm_group_label>
    <other_name>neoprofen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All neonates (0-29 days old) less than or equal to 33 post-menstrual age at time of
             PDA diagnosis requiring nasal CPAP or mechanical ventilation

          -  Echo confirmed PDA with a transductal diameter of 1.5 mm or greater and demonstrating
             a left-to-right shunt

          -  Signed informed consent

        Exclusion Criteria:

          -  Presence of: ductal-dependent congenital heart disease, pulmonary hypertension,

          -  Active bleeding (including Grade 3 or 4 IVH)

          -  Platelet count &lt; 100,000

          -  Coagulopathy

          -  Suspected NEC

          -  Suspected perforation

          -  Creatinine &gt; 1.5

          -  Hyperbilirubinemia requiring exchange transfusion

          -  Hypotension requiring pressor support

          -  Life-threatening congenital malformation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>29 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Hocker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSF Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Illinois at OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <last_update_submitted>January 25, 2014</last_update_submitted>
  <last_update_submitted_qc>January 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OSF Healthcare System</investigator_affiliation>
    <investigator_full_name>James Hocker</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>PDA</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Preterm</keyword>
  <keyword>Neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

